Searched for
ELI LILLY 2024 PROFIT FORECAST
No smooth landing: ICRA sees Indian airlines' losses widening up to Rs 38,000 crore in FY27India's aviation sector faces a grim outlook, with ICRA projecting net losses to skyrocket to ₹36,000-38,000 crore in FY27. This sharp revi...- US stocks | Micron overtakes Meta, Tesla in market value amid relentless AI infrastructure demandMemory chip giant Micron Technology has surpassed Meta Platforms in market valuation for the first time, driven by a robust AI-fueled surge...
- AI is plowing through the workplace. This new group wants to help people adapt and have jobsA newly formed bipartisan nonprofit named RAISE US is set to launch with over $500 million aimed at tackling job losses anticipated from ar...
- Centre set to tighten oversight of pharma packaging materialsIndia is set to implement a mandatory registration for printed pharmaceutical packaging manufacturers to combat counterfeit drugs. This mov...
- Eli Lilly launches cancer drug Tanstrive in IndiaThe launch follows marketing authorisation from the Central Drugs Standard Control Organisation (CDSCO) for patients with locally advanced ...
- European shares gain as upbeat Micron forecast revives AI rallyEuropean markets opened on a positive note, driven by a surge in technology stocks. Strong forecasts from US chipmakers Micron and Qualcomm...
- Nikkei marks record closing high as AI shares rally on Micron forecastTokyo's Nikkei index soared to a record high, surging over 4% on Thursday. This significant jump was fueled by a powerful rally in AI-relat...
- Psychology suggests people who check the weather twice before leaving aren’t obsessive: They’re reducing uncertainty before the day begins, because predictability frees attention for everything else that needs itChecking the weather forecast a couple of times before stepping outside is not merely a signal of anxiety. Instead, it serves as a sensible...
- Global Markets | Japan's Nikkei posts sharpest weekly gain in nearly two years on AI shares rallyJapan's Nikkei index celebrated its most significant weekly surge in nearly two years, hitting unprecedented levels day after day. The exci...
- Jabil raises annual profit forecast amid strong data center demandJabil has raised its profit forecast for 2026, fueled by a surge in demand from AI-powered data centers. This boom in infrastructure invest...
- Trump's unusual stock frenzy: Portfolio shows 3,600 trades in 90 daysTrump's investment accounts saw thousands of trades totaling hundreds of millions of dollars between January and March. This feverish activ...
- Kiran Mazumdar-Shaw eyes crown of world’s top insulin supplier for BioconIndian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalising on growing demand as major pharmaceutic...
- Global drugmakers rush to boost US presence as tariff threat loomsGlobal drug companies are boosting U.S. production and stockpiling medicines. This is a response to potential tariffs on branded drugs. Com...
- India's Electronics Mart eyes new markets as tech hubs fear job lossesElectronics Mart India is diversifying its store presence beyond Hyderabad due to concerns about potential AI-driven job losses impacting c...
- Eli Lilly's Alzheimer's drug donanemab approved in India, but neurologists flag cost, access barriersA new drug for Alzheimer's, donanemab, has arrived in India. It aims to slow the disease's progression by clearing brain plaques. While off...
- India's weight-loss drug boom raises questions over healthcare prioritiesIndia's market for cheaper anti-obesity drugs has surged tenfold. While demand is high, especially among those with diabetes, concerns abou...
- UK approves Novo weight-loss pill to edge open European marketBritain's medicine regulator has approved Novo Nordisk's weight-loss pill. This makes the UK the first European market for the oral treatme...
- US stocks: Musk's SpaceX prices record $75 billion IPO at $135 a shareSpaceX has priced its record-breaking U.S. IPO at $135 per share, raising $75 billion and valuing the company at $1.77 trillion. This makes...
- US stocks: Lilly shares rise on hopes that next-gen drug will extend lead in weight-loss marketLilly presented full data from two retatrutide trials, one in treatment naive type 2 diabetes patients and another in patients with obesity...
- Eli Lilly says next-gen obesity drug curbs sleep apnea, among other benefitsEli Lilly presented trial results for its new obesity drug retatrutide. The drug significantly reduced sleep apnea severity and knee osteoa...
Load More
